288 related articles for article (PubMed ID: 24472710)
1. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides.
Reardon ZD; Patel SG; Zaid HB; Stimson CJ; Resnick MJ; Keegan KA; Barocas DA; Chang SS; Cookson MS
Eur Urol; 2015 Jan; 67(1):165-170. PubMed ID: 24472710
[TBL] [Abstract][Full Text] [Related]
2. Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer.
McFerrin C; Davaro F; May A; Raza S; Siddiqui S; Hamilton Z
Investig Clin Urol; 2020 Nov; 61(6):565-572. PubMed ID: 32985142
[TBL] [Abstract][Full Text] [Related]
3. Determinants of neoadjuvant chemotherapy for urothelial muscle-invasive bladder cancer: Does location matter?
Monaghan TF; Robins DJ; Suss NR; Miller CD; Flores VX; Smith MT; Weiss JP; McNeil BK; Winer AG
Int J Clin Pract; 2021 Aug; 75(8):e14262. PubMed ID: 33887115
[TBL] [Abstract][Full Text] [Related]
4. A population-based retrospective analysis on variation in use of neoadjuvant chemotherapy depending on comorbidity in patients with muscle-invasive bladder cancer undergoing cystectomy in Denmark in the period 2013-2019.
Körner SK; Jensen JB
Scand J Urol; 2022 Feb; 56(1):34-38. PubMed ID: 34775886
[TBL] [Abstract][Full Text] [Related]
5. Age related trends in the utilization of neoadjuvant chemotherapy for muscle invasive bladder cancer.
Kohut-Jackson A; Orf J; Barresi D; Davaro F; Hamilton Z
Urol Oncol; 2024 May; 42(5):160.e25-160.e31. PubMed ID: 38238117
[TBL] [Abstract][Full Text] [Related]
6. Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer.
Carvalho FL; Zeymo A; Egan J; Kelly CH; Zheng C; Lynch JH; Hwang J; Stamatakis L; Krasnow RE; Kowalczyk KJ
Investig Clin Urol; 2020 Jul; 61(4):390-396. PubMed ID: 32665995
[TBL] [Abstract][Full Text] [Related]
7. Trends in Treatment Strategies and Comparison of Outcomes in Lymph Node Positive Bladder Cancer: An Analysis of the National Cancer Database.
Darwish C; Sparks A; Amdur R; Reddy A; Whalen M
Urology; 2020 Dec; 146():168-176. PubMed ID: 32866509
[TBL] [Abstract][Full Text] [Related]
8. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy.
Bree KK; Hensley PJ; Westerman ME; Kokorovic A; Nogueras-Gonzalez GM; Dinney CP; Kamat AM; Navai N
J Urol; 2021 Sep; 206(3):577-585. PubMed ID: 33872050
[TBL] [Abstract][Full Text] [Related]
9. Income Disparities in Survival and Receipt of Neoadjuvant Chemotherapy and Pelvic Lymph Node Dissection for Muscle-Invasive Bladder Cancer.
Antar RM; Xu VE; Adesanya O; Drouaud A; Longton N; Gordon O; Youssef K; Kfouri J; Azari S; Tafuri S; Goddard B; Whalen MJ
Curr Oncol; 2024 May; 31(5):2566-2581. PubMed ID: 38785473
[No Abstract] [Full Text] [Related]
10. Determinants of adequate lymph node dissection following neoadjuvant chemotherapy in patients with urothelial muscle-invasive bladder cancer: results from the National Cancer Database.
Monaghan TF; Flores VX; Suss NR; Robins DJ; Smith MT; McNeil BK; Hyacinthe LM; Weiss JP; Winer AG
Int Urol Nephrol; 2021 Feb; 53(2):235-239. PubMed ID: 32865771
[TBL] [Abstract][Full Text] [Related]
11. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
Necchi A; Raggi D; Gallina A; Ross JS; Farè E; Giannatempo P; Marandino L; Colecchia M; Lucianò R; Bianchi M; Colombo R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Capitanio U; Montorsi F; de Jong JJ; Dittamore R; Liu Y; Davicioni E; Boormans JL; Briganti A; Black PC; Gibb EA
Eur Urol; 2020 Jun; 77(6):701-710. PubMed ID: 32165065
[TBL] [Abstract][Full Text] [Related]
12. Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy.
Hensley PJ; Bree KK; Campbell MT; Alhalabi O; Kokorovic A; Miest T; Nogueras-Gonzalez GM; Gao J; Siefker-Radtke AO; Guo CC; Navai N; Dinney CP; Kamat AM
J Urol; 2021 Nov; 206(5):1258-1267. PubMed ID: 34184926
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant versus Adjuvant Chemotherapy in Patients with Resectable Muscle-Invasive Bladder Cancer.
Sawasdee A; Tanthanuch M; Bejrananda T
Asian Pac J Cancer Prev; 2022 Nov; 23(11):3641-3647. PubMed ID: 36444575
[TBL] [Abstract][Full Text] [Related]
14. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain R; Chahoud J; Poch M; Manley BJ; Li R; Sexton W; Gilbert SM
J Urol; 2021 Oct; 206(4):924-932. PubMed ID: 34032503
[TBL] [Abstract][Full Text] [Related]
15. Increasing utilization of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the United States.
Keegan KA; Zaid HB; Patel SG; Chang SS
Curr Urol Rep; 2014 Apr; 15(4):394. PubMed ID: 24566815
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
Osanto S; Álvarez Gómez de Segura C
Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
[TBL] [Abstract][Full Text] [Related]
18. The role of neoadjuvant chemotherapy, lymph node dissection, and treatment delay in patients with muscle-invasive bladder cancer undergoing partial cystectomy.
Lenis AT; Fero KE; Ojeaburu L; Lec PM; Golla V; Brisbane W; Leapman MS; Chamie K
Urol Oncol; 2021 Aug; 39(8):496.e17-496.e24. PubMed ID: 33640225
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with utilization of neoadjuvant chemotherapy in charlson comorbidity zero non-metastatic muscle-invasive bladder cancer patients.
Au D; Lee EK; Popoola TO; Parker WP; Onge JMS; Ellis SD
Int Braz J Urol; 2021; 47(4):803-818. PubMed ID: 33848073
[TBL] [Abstract][Full Text] [Related]
20. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
Becker REN; Meyer AR; Brant A; Reese AC; Biles MJ; Harris KT; Netto G; Matoso A; Hoffman-Censits J; Hahn NM; Choi W; McConkey D; Pierorazio PM; Johnson MH; Schoenberg MP; Kates MR; Baras A; Bivalacqua TJ
Eur Urol; 2021 Mar; 79(3):364-371. PubMed ID: 32814637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
